Depletion of either CXCR2+ or CCR2+ tumor‐associated macrophages has been shown to augment antitumor immunity.[58] Our study demonstrated that tumor inhibition was observed following treatment with CXCR2 and CCR2 inhibitors, whereas the loss of Ccn1 in pancreatic cancer cells does not induce a response. The gene discussed is CCR2; the disease is pancreatic neoplasm.